4743.TWO实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 11:35):

Stats
今日成交量	907 207
平均成交量	2.17M
市值	72.70B
EPS	TWD0 ( 2024-03-05 )
下一个收益日期	( TWD0 ) 2024-05-09
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	-48.63
ATR14	TWD0.161 (0.10%)

音量相关性

長: 0.03 (neutral)

短: 0.75 (moderate)

Signal:(43.601) Neutral

Oneness Biotech Co., Ltd. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Oneness Biotech Co., Ltd. 相关性 - 货币/商品

0.10
( neutral )

0.11
( neutral )

0.00
( neutral )

-0.02
( neutral )

0.14
( neutral )

Oneness Biotech Co., Ltd. 财务报表

Annual	2023
营收:	TWD86.78M
毛利润:	TWD-381.69M (-439.82 %)
EPS:	TWD-2.91

FY	2023
营收:	TWD86.78M
毛利润:	TWD-381.69M (-439.82 %)
EPS:	TWD-2.91

FY	2022
营收:	TWD1.07B
毛利润:	TWD844.39M (79.24 %)
EPS:	TWD0.820

FY	2021
营收:	TWD65.77M
毛利润:	TWD45.04M (68.49 %)
EPS:	TWD-1.060

Financial Reports:

No articles found.

Oneness Biotech Co., Ltd.

Oneness Biotech Co., Ltd engages in the research and development of new drugs, and sale of pharmaceutical and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis and systemic sclerosis; FB825, which is in Phase II clinical trial for treating atopic dermatitis, allergic diseases, and asthma; and FB918, a human monoclonal antibody, which is in pre-clinical stage for the treatment of allergic asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and sale of agricultural products. The company was incorporated in 2008 and is headquartered in Taipei City, Taiwan.